UCB: Positive data in myasthenia gravis with zilucoplan phase 3 study

 

- Positive topline results show the Phase 3 RAISE (NCT04115293) zilucoplan trial met primary and all key secondary endpoints in adults with generalized myasthenia gravis
- The results show a favorable safety profile and good tolerability
- UCB plans to proceed with zilucoplan regulatory submissions later this year
- Results follow recent positive topline data from the Phase 3 MycarinG study investigating rozanolixizumab, a monoclonal antibody also being developed by UCB in the same indication
- These results are the latest in a series of positive phase 3 data announcements by the company across its product pipeline

https://www.biospace.com/article/releases/ucb-announces-positive-data-in-myasthenia-gravis-with-zilucoplan-phase-3-study-results/